TissueTinker
Develops proprietary 3D bioprinted tumor organoids using tissue-specific bioinks to replicate tumor microenvironments for cancer drug testing, replacing 2D cell cultures and animal trials.
- CEO / Founder
- Benjamin Ringler
- Team Size
- 1-10
- Stage
- Active
- Total Funding
- $6.96K
- Latest Round
- Grant
- Key Investors
- McGill Innovation Fund, Centech, University of New Brunswick
Technology & Products
Key Products
3D bioprinted tumor organoids; Tissue-specific bioinks; Ready-to-print tumor model designs
Technological Advantage
Bioink formulation tailored to replicate intercellular and cell-matrix interactions driving cancer growth; automated 3D cell culture through bioprinting system enabling high-throughput model production.
Differentiation
Value Proposition
Provides human-relevant 3D tumor models that replicate cancer growth and metastasis, enabling more accurate preclinical drug testing and potentially reducing drug development costs and time.
How They Differentiate
Focuses specifically on 3D bioprinted tumor models with tissue-specific bioinks rather than general bioinks or organ-on-chip platforms; creates miniaturized models (300 microns) optimized for cancer research.
Market & Competition
Target Customers
Biopharmaceutical companies, cancer researchers, academic institutions
Industry Verticals
Pharmaceuticals; Biotechnology; Medical Research
Competitors
Aspect Biosystems, Organovo
Growth & Milestones
Major Milestones
Selected for L2M Validate Quebec 2025 program; Featured in McGill University spinoff portfolio; Media coverage in 3D printing industry publications